This summary does not address all of the risks that we face. 8226;ALLO-715 plus nirogacestat. We are currently utilizing ALLO-647 in all of our clinical trials. 8226;Expand our leadership position within hematologic indications. We also believe our approach is unique and differentiated. The median time from enrollment to the start of therapy was five days. This patient is reflected as a PR in the table above and not as a CR. These patients were also refractory to allogeneic CAR T therapy. We believe BCMA is an appropriate target for the treatment of multiple myeloma. We expect to report updated data from the UNIVERSAL trial in the fourth quarter of 2021. We also plan to investigate the use of ALLO-316 for a second indication in R/R AML. We expect to initiate the TRAVERSE trial in the first quarter of 2021. FLT3 is a receptor tyrosine kinase that is overactive in AML blasts. Some preclinical testing may continue even after the IND is submitted. The term remuneration has been interpreted broadly to include anything of value. As a result, increasingly high barriers are being erected to the entry of new products. Coverage policies and third-party reimbursement rates may change at any time. We cannot predict, however, how changes in these laws may affect our future operations. We take ownership and get things done. As of December 31, 2020, we had an accumulated deficit of $646.3 million. Clinical testing is expensive, time consuming and subject to uncertainty. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. As a result, we may never be able to develop a commercially viable product. For additional information regarding our competition, see "Item 1. As of February 1, 2021, we had 265 full-time employees. In addition, there is a natural transition period when a new third party commences work. We also face competition for supplies from other cell therapy companies. Such a loss of patent protection could have a material adverse impact on our business. We may not be able to protect our intellectual property rights outside the United States.
